MCID: CHY006
MIFTS: 32

Chylous Ascites malady

Categories: Rare diseases, Cardiovascular diseases, Fetal diseases

Aliases & Classifications for Chylous Ascites

About this section
Sources:
45NIH Rare Diseases, 51Orphanet, 65UMLS, 47Novoseek, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Chylous Ascites:

Name: Chylous Ascites 45 51 65
Congenital Chylous Ascites 45 65
 
Ascites Chylous 47

Characteristics:



Classifications:



External Ids:

Orphanet51 1160
ICD10 via Orphanet28 I89.8
MESH via Orphanet37 D002915
UMLS via Orphanet66 C0008732
UMLS65 C0008732, C2930811

Summaries for Chylous Ascites

About this section
MalaCards based summary: Chylous Ascites, also known as congenital chylous ascites, is related to leukemia and breast cancer, and has symptoms including lymphedema, abnormality of the skin and neoplasm. An important gene associated with Chylous Ascites is ALB (Albumin). Affiliated tissues include skin, endothelial and breast.

Related Diseases for Chylous Ascites

About this section

Graphical network of the top 20 diseases related to Chylous Ascites:



Diseases related to chylous ascites

Symptoms for Chylous Ascites

About this section

Symptoms:

 51 (show all 7)
  • ascitis
  • lymphedema
  • subcutaneous nodules/lipomas/tumefaction/swelling
  • glaucoma
  • intestinal/colonic anomaly
  • pancreatitis
  • neoplasms/tumors

HPO human phenotypes related to Chylous Ascites:

(show all 8)
id Description Frequency HPO Source Accession
1 lymphedema hallmark (90%) HP:0001004
2 abnormality of the skin typical (50%) HP:0000951
3 neoplasm occasional (7.5%) HP:0002664
4 abnormality of the intestine occasional (7.5%) HP:0002242
5 pancreatitis occasional (7.5%) HP:0001733
6 glaucoma occasional (7.5%) HP:0000501
7 chylous ascites HP:0012281
8 glaucoma HP:0000501

Drugs & Therapeutics for Chylous Ascites

About this section

Drugs for Chylous Ascites (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Octreotideapproved, investigationalPhase 219883150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
 
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Ocphyl
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatin
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
2
SomatostatinPhase 215351110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
3Gastrointestinal AgentsPhase 26401
4Antineoplastic Agents, HormonalPhase 24256

Interventional clinical trials:

idNameStatusNCT IDPhase
1Treatment With Octreotide in Patients With LymphangioleiomyomatosisCompletedNCT00005906Phase 2

Search NIH Clinical Center for Chylous Ascites

Genetic Tests for Chylous Ascites

About this section

Anatomical Context for Chylous Ascites

About this section

MalaCards organs/tissues related to Chylous Ascites:

33
Skin, Endothelial, Breast, Colon, T cells, Brain, Lymph node

Animal Models for Chylous Ascites or affiliated genes

About this section

Publications for Chylous Ascites

About this section

Articles related to Chylous Ascites:

(show top 50)    (show all 542)
idTitleAuthorsYear
1
Guidelines and Pathways for Clinical Practice in Tendinopathy: Their Role and Development. (27136286)
2015
2
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group. (26460295)
2015
3
Interaction between p12CDK2AP1 and a novel unnamed protein product inhibits cell proliferation by regulating the cell cycle. (24248101)
2014
4
Congenital hydronephrosis: disease or condition? (25532093)
2014
5
An unusual presentation of meningococcal meningitis--timely recognition can save lives! (23602741)
2013
6
Electroconvulsive therapy in adolescents with intellectual disability and severe self-injurious behavior and aggression: a retrospective study. (22923049)
2013
7
Molecular mechanism of ventricular trabeculation/compaction and the pathogenesis of the left ventricular noncompaction cardiomyopathy (LVNC). (23843320)
2013
8
Genotyping of Malassezia pachydermatis isolates from canine healthy skin and lesional skin of atopic dermatitis in Japan, Korea and Taiwan. (23411408)
2013
9
Frequency of non-convulsive seizures and non-convulsive status epilepticus in subarachnoid hemorrhage patients in need of controlled ventilation and sedation. (22932991)
2012
10
Heparanase enzyme in chronic inflammatory bowel disease and colon cancer. (22331282)
2012
11
Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2. (22270964)
2012
12
Myasthenia gravis with antibodies to MuSK: another step toward solving mystery? (22013184)
2011
13
Polyalanine expansion of PHOX2B in congenital central hypoventilation syndrome: rs17884724:A>C is associated with 7-alanine expansion. (19881470)
2010
14
Commentary on the paper "Is alexithymia a risk factor for major depression, personality disorder, or alcohol use disorders? A prospective population-based study". (20159213)
2010
15
Neuroprotective mechanisms of puerarin in middle cerebral artery occlusion-induced brain infarction in rats. (19272172)
2009
16
Cloning, expression and immunolocalization of alpha1-adrenoceptor in different tissues from rhesus monkey and human male reproductive tract. (18204069)
2008
17
Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. (17574038)
2007
18
Methemoglobinemia and benzocaine. (18049203)
2007
19
Kinase-active interleukin-1 receptor-associated kinases promote polyubiquitination and degradation of the Pellino family: direct evidence for PELLINO proteins being ubiquitin-protein isopeptide ligases. (17675297)
2007
20
Expression of keratinocyte growth factor and keratinocyte growth factor receptor and its impact on Hela cells]. (17593825)
2007
21
Primary aldosteronism caused by a unilateral adrenal adenoma accompanied by autonomous cortisol secretion. (17541216)
2007
22
Lifetime illicit drug use and drug dependence are common by the age of 25 in New Zealand. (16868205)
2006
23
Pharmacology of nitric oxide: molecular mechanisms and therapeutic strategies. (15134564)
2004
24
Induced sputum versus bronchoalveolar lavage during acute chest syndrome in sickle cell disease. (12969866)
2003
25
Good to CU. (12840737)
2003
26
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. (12517256)
2003
27
A quasi-tetrahedral Cu4 cluster and a helical-chain copper (II) complex with single syn-anti carboxylate bridges: crystal structure and magnetic properties. (12817958)
2003
28
Omphalocele: clinical review and surgical experience using dura patch grafts. (12152643)
2002
29
HLA class I polymorphism in a Moroccan population from Casablanca. (12047355)
2002
30
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives. (11391857)
2001
31
Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. (11265775)
2001
32
A novel population of B7-1+ T cells producing intracellular IL-4 is decreased in patients with multiple sclerosis. (10940899)
2000
33
Mex67p of Schizosaccharomyces pombe interacts with Rae1p in mediating mRNA export. (11073978)
2000
34
Reduced sensitivity of HeLa cells to cis-platinum by simultaneous overexpression of copper, zinc-superoxide dismutase and catalase. (9952318)
1999
35
Inositol 1,4,5-trisphosphate receptor type 1 is a substrate for caspase-3 and is cleaved during apoptosis in a caspase-3-dependent manner. (10567423)
1999
36
Growth retardation, alopecia, pseudoanodontia, and optic atrophy (GAPO syndrome) with congenital glaucoma. (9230846)
1997
37
Major vault protein LRP-related multidrug resistance. (8763338)
1996
38
Tachykinin NK1 and NK2 receptors mediate the non-cholinergic bronchospastic response to capsaicin and vagal stimulation in guinea-pigs. (7538136)
1995
39
Divergent myosarcomatous differentiation in retroperitoneal liposarcoma. (8333554)
1993
40
de novo mutation causes steroid 21-hydroxylase deficiency in one family of HLA-identical affected and unaffected siblings. (8325964)
1993
41
Treatment of severe steatorrhea with ox bile in an ileectomy patient with residual colon. (1587199)
1992
42
Spatial relationship of nebulin relative to other myofibrillar proteins during myogenesis in embryonic chick skeletal muscle cells in vitro. (1556170)
1992
43
Human T-cell lymphotropic virus type I (HTLV-I) transcriptional activator, Tax, enhances CREB binding to HTLV-I 21-base-pair repeats by protein-protein interaction. (1386673)
1992
44
Evaluation of adult idiopathic growth hormone deficiency with other pituitary hormones deficiency]. (2171885)
1990
45
Non-epileptic myoclonus and mitochondrial encephalomyopathy. (2619613)
1989
46
Gastrinoma (Zollinger-Ellison Syndrome) in the Dog and cat. (17423047)
1988
47
Surgical pathology of olfactory neuroblastoma. (6490385)
1984
48
Human spleen histone H2B. Isolation and amino acid sequence. (422550)
1979
49
ACTH test for adrenocortical insufficiency. (4319981)
1970
50
Exfoliative Dermatitis in the Newborn. (20784441)
1942

Variations for Chylous Ascites

About this section

Expression for genes affiliated with Chylous Ascites

About this section
Search GEO for disease gene expression data for Chylous Ascites.

Pathways for genes affiliated with Chylous Ascites

About this section

GO Terms for genes affiliated with Chylous Ascites

About this section

Sources for Chylous Ascites

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet